At a glance
- Originator Eisai Co Ltd
- Class Antineoplastics
- Mechanism of Action Farnesyltranstransferase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 30 May 2001 Profile reviewed but no significant changes made
- 23 Oct 1997 No-Development-Reported for Cancer in Japan (Unknown route)
- 05 Jan 1996 Preclinical development for Cancer in Japan (Unknown route)